Endonovo Targets Dept. of Defense, VA & Federal Contracts
January 03, 2023 09:09 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical...
Endonovo Launches Telehealth Initiative
December 13, 2022 09:11 ET
|
Endonovo Therapeutics, Inc.
Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the...
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
July 28, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior...
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
April 25, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, April 25, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and...
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
October 08, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today a new marketing and public awareness campaign around their FDA...
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
July 21, 2020 09:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced the Company’s registration statement on Form S-1 relating...
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
June 15, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the first quarter...
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
May 04, 2020 08:15 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 04, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today reported financial results for fiscal year ended December 31, 2019. ...
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
March 25, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 25, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces the intent to distribute of SofPulse®...
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
March 02, 2020 07:30 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 02, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced it has filed an 8K with the Securities and Exchange...